Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

Overview

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Investigator)
  • Study Primary Completion Date: October 2007

Interventions

  • Drug: bimatoprost 0.03% eye drops
    • bimatoprost 0.03% 1 drop nightly for 3 months
  • Drug: travoprost 0.004% eye drops
    • travoprost 0.004% 1 drop nightly for 3 months

Arms, Groups and Cohorts

  • Experimental: 1
  • Active Comparator: 2

Clinical Trial Outcome Measures

Primary Measures

  • Intraocular Pressure (IOP)
    • Time Frame: Month 3
    • Intraocular Pressure

Secondary Measures

  • Tolerability – Conjunctival Hyperemia
    • Time Frame: Month 3
    • Conjunctival Hyperemia: Number of participants with at least 1 grade increase in severity from baseline. A five grade scale from 0 to 3 (0 = none, +0.5 = trace, 1 = mild, 2 = moderate, 3 = severe)

Participating in This Clinical Trial

Inclusion Criteria

  • Glaucoma or ocular hypertension in both eyes – Currently being treated with latanoprost 0.005% daily and in need of additional IOP-lowering – Best-corrected visual acuity of 20/100 or better in each eye – Visual field within 6 months of study entry Exclusion Criteria:

  • Secondary glaucoma – Active intraocular inflammation or macular edema – Intraocular surgery or laser surgery within the past 3 months

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Allergan
  • Provider of Information About this Clinical Study
    • Medical Affairs Director, Allergan, Inc.
  • Overall Official(s)
    • Medical Affairs, Study Director, Allergan

References

Kammer JA, Katzman B, Ackerman SL, Hollander DA. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study. Br J Ophthalmol. 2010 Jan;94(1):74-9. doi: 10.1136/bjo.2009.158071. Epub 2009 Sep 1.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.